Parotidectomy (Parotid Gland Removal): Surgery, Indications, and Outcomes — Cost, Top Hospitals & Success Rates | MyMedicPlus

Parotidectomy is the surgical removal of part or all of the parotid gland — the largest of the three paired major salivary glands, located anterior and inferior to the ear, overlying the masseter muscle and the ramus of the mandible. The parotid gland produces serous saliva and accounts for approximately 25% of total resting saliva production. It is the most common site of salivary gland neoplasms, accounting for 70–80% of all salivary gland tumours.

The parotid gland is anatomically divided into superficial and deep lobes by the facial nerve (cranial nerve VII) and its branches, which course through the substance of the gland. This intimate anatomical relationship is the defining feature of parotid surgery — the facial nerve is never truly covered by glandular tissue but rather embedded within the parotid as it divides from the main trunk (exiting the stylomastoid foramen) into its five terminal branches: the temporal, zygomatic, buccal, marginal mandibular, and cervical branches, collectively supplying all muscles of facial expression. The superficial lobe contains approximately 80% of the gland mass; the deep lobe lies medial to the facial nerve and is separated from the parapharyngeal space by the styloid process and stylomandibular ligament.

The indication for parotidectomy encompasses both benign and malignant parotid neoplasms, as well as chronic inflammatory conditions refractory to conservative management. The procedure ranges from superficial (lateral) parotidectomy — removing the superficial lobe with facial nerve preservation — to total parotidectomy (removing both lobes with nerve preservation) and radical parotidectomy (en bloc removal of the gland and facial nerve for high-grade malignancy with nerve involvement). The extent of surgery is determined by tumour histology, location (superficial vs deep lobe), clinical staging, and intraoperative frozen section findings.

Parotidectomy addresses a broad range of benign and malignant parotid pathologies:

• Pleomorphic adenoma (mixed salivary tumour): The most common benign parotid neoplasm, accounting for 60–70% of all parotid tumours and 80% of benign parotid masses. Characterised by mixed epithelial and mesenchymal components with a fibrous pseudocapsule that is frequently incomplete and satellite nodule-bearing. Without adequate treatment, pleomorphic adenomas carry a 5–10% lifetime risk of malignant transformation to carcinoma ex pleomorphic adenoma. The CAMS/BSOMS (Salivary Gland Clinical Practice Guideline, UK, 2021) strongly recommends superficial parotidectomy over simple enucleation for pleomorphic adenoma in the superficial lobe, as enucleation has a 20–45% local recurrence rate due to incomplete pseudocapsule and satellite nodule removal, while superficial parotidectomy reduces recurrence to below 2%.
• Warthin's tumour (cystadenolymphoma): The second most common benign parotid neoplasm, accounting for 5–10% of parotid tumours. Strongly associated with smoking; bilateral in 10–15% of cases. Occurs predominantly in older males. Histologically benign with virtually no malignant potential. Management options include surgical excision (superficial parotidectomy) or active surveillance for small, asymptomatic, confirmed Warthin's tumours in elderly patients.
• Mucoepidermoid carcinoma: The most common malignant salivary gland tumour, occurring in the parotid in 45–50% of cases. Graded as low, intermediate, or high grade based on the proportion of mucous, intermediate, and epidermoid cells. Low-grade mucoepidermoid carcinoma carries an excellent prognosis (90–95% 5-year disease-specific survival) after complete surgical excision. High-grade mucoepidermoid carcinoma behaves aggressively, requiring total parotidectomy with elective or therapeutic neck dissection and postoperative radiotherapy.
• Adenoid cystic carcinoma: Characterised by perineural invasion as its hallmark feature, causing pain and potential facial nerve infiltration. Skip lesions along the facial nerve require adequate surgical margins. Adjuvant radiotherapy is almost universally recommended given its propensity for recurrence.
• Acinic cell carcinoma, salivary duct carcinoma, carcinoma ex pleomorphic adenoma: Each managed with surgery ± adjuvant therapy based on stage, grade, and resection margin status.
• Chronic recurrent parotitis and parotid duct obstructive disease: Recurrent parotid sialadenitis with ductal calculi refractory to sialendoscopy and salivary duct lithotripsy may ultimately require parotidectomy to prevent recurrent infections.

Patient selection for parotidectomy involves clinical, radiological, and histopathological evaluation to determine the optimal surgical extent:

Preoperative assessment:

• Clinical evaluation — parotid mass characteristics (size, consistency, mobility, skin involvement, pain, facial nerve function), cervical lymphadenopathy, and systemic symptoms.
• Imaging — ultrasound with fine needle aspiration cytology (FNAC) is the first-line investigation for any parotid mass. MRI with gadolinium is the preferred cross-sectional imaging modality for deep lobe tumours, parapharyngeal space extension, perineural spread, and lymph node assessment. CT is complementary, particularly for mandibular or skull base involvement by malignancy.
• Fine needle aspiration cytology (FNAC) — mandatory before surgery for parotid masses. Provides histological characterisation and guides operative planning. Core biopsy of the parotid is generally avoided due to facial nerve risk and risk of seeding for pleomorphic adenoma.

Surgical eligibility by tumour type:

• Superficial lobe benign tumour (pleomorphic adenoma, Warthin's): Superficial parotidectomy is the standard operation. Patients of any age fit for general anaesthesia are eligible. The CAMS/BSOMS guideline confirms that excision with a cuff of normal parotid tissue is mandatory for pleomorphic adenoma.
• Deep lobe tumour: Total parotidectomy with facial nerve preservation is required. Deep lobe tumours are more technically demanding, with the facial nerve elevated out of the deep lobe before gland excision.
• Malignant parotid tumour: Staging CT of chest and MRI of neck and skull base is performed. PET-CT may be added for high-grade malignancy. Multidisciplinary team (head and neck MDT) review determines surgical extent, neck dissection indication, and need for adjuvant radiotherapy or chemotherapy.
• Patients with pre-existing facial nerve weakness: Mandatory assessment distinguishes pre-operative nerve involvement by tumour (requiring nerve sacrifice) from incidental pre-existing paresis. Electromyography of facial muscles may be used to assess baseline nerve function.
• Fitness for surgery: Parotidectomy is performed under general anaesthesia, typically taking 1.5–3 hours for superficial parotidectomy and 3–5 hours for complex total or radical procedures. Patients must be assessed for cardiovascular, respiratory, and anaesthetic fitness.

The surgical approach and extent of resection are tailored to tumour size, location, histology, and involvement of the facial nerve:

Superficial (Lateral) Parotidectomy

The standard procedure for benign tumours of the superficial lobe. A modified Blair or Lazy-S incision extends from the preauricular crease downward around the earlobe and posteriorly into the hairline, then forward into the neck along a skin crease. Skin flaps are elevated to expose the parotid fascia. The facial nerve is identified at the stylomastoid foramen (using the tragal pointer, posterior belly of digastric, or tympanomastoid suture as landmarks), and each branch is traced anteriorly through the gland. The superficial lobe and tumour are excised with a cuff of surrounding parotid tissue while preserving all facial nerve branches. Intraoperative facial nerve monitoring with continuous EMG electromyography is essential.

Total Parotidectomy with Facial Nerve Preservation

Performed for deep lobe tumours, large benign tumours straddling both lobes, or cases where adequate surgical margins cannot be achieved by superficial parotidectomy alone. After superficial lobe removal and facial nerve dissection, the deep lobe is mobilised medially to the nerve by retracting the nerve branches superiorly, allowing removal of the deep lobe below. Longer operative time (3–4 hours) and higher facial nerve manipulation risk.

Total Parotidectomy with Facial Nerve Sacrifice (Radical Parotidectomy)

Indicated when the facial nerve is directly invaded by malignant tumour — confirmed by preoperative MRI perineural spread or intraoperative frozen section of nerve. The facial nerve is sacrificed at the level of involvement. Immediate facial nerve reconstruction using cable graft (great auricular nerve, sural nerve) is performed at the time of surgery where possible, providing a pathway for nerve regeneration over 12–18 months. In high-grade parotid malignancy, radical parotidectomy is combined with ipsilateral modified radical neck dissection (levels I–V) and postoperative radiotherapy (60–66 Gy in 30–33 fractions) with or without concurrent cisplatin-based chemotherapy.

Intraoperative Facial Nerve Monitoring

Continuous EMG facial nerve monitoring (using electrodes placed in the orbicularis oculi and orbicularis oris muscles) provides real-time feedback on nerve integrity throughout dissection. Mechanical stimulation triggers EMG bursts, alerting the surgeon to inadvertent nerve contact. Electrical direct nerve stimulation (0.3–1.0 mA) confirms nerve function at any point during dissection. IONM significantly reduces the risk of permanent facial nerve injury in experienced hands and is recommended by CAMS/BSOMS guidelines for all parotid surgery.

Minimally Invasive and Endoscopic Approaches

Retroauricular endoscopic and robot-assisted remote access parotidectomy (transaxillary or facelift approach) are available at specialist centres for select small benign tumours in cosmetically sensitive patients. Oncological adequacy must not be compromised for cosmetic advantage.

Parotidectomy — when performed by an experienced head and neck surgeon — achieves excellent oncological and functional outcomes across the spectrum of parotid disease:

• Definitive cure for pleomorphic adenoma: Superficial parotidectomy with a cuff of normal tissue reduces local recurrence of pleomorphic adenoma to below 2% at 10 years (compared to 20–45% with enucleation alone). Preventing recurrence is critical — recurrent pleomorphic adenoma is multinodular, disseminated throughout the parotid bed, and extremely difficult to re-excise without facial nerve sacrifice.
• Prevention of malignant transformation: Since untreated pleomorphic adenomas have a 5–10% lifetime risk of transformation to carcinoma ex pleomorphic adenoma (much higher with recurrent or long-standing tumours), surgical resection eliminates this risk entirely.
• Oncological control for malignant tumours: For low-grade malignancies (low-grade mucoepidermoid carcinoma, acinic cell carcinoma), complete surgical excision achieves 5-year disease-specific survival rates above 90%. For high-grade tumours, combined modality therapy (radical surgery + radiotherapy ± chemotherapy) achieves locoregional control in 60–80% of patients.
• Symptom resolution: Patients with enlarging, cosmetically disfiguring, or symptomatic parotid masses benefit from relief of mass effect, pain, and cosmetic concern. Patients with recurrent parotid infections (chronic sialadenitis) achieve permanent resolution of infective episodes.
• Facial nerve function preservation: With meticulous technique, intraoperative monitoring, and experienced surgical teams, permanent facial nerve palsy rates for superficial parotidectomy for benign disease are below 1–2%. Temporary neuropraxia (transient postoperative facial weakness) resolves within 6 weeks to 6 months in the vast majority of cases (above 95%).
• Quality-of-life outcomes: FACE-Q and FaCE (Facial Clinimetric Evaluation) questionnaire studies consistently show high patient satisfaction with function and appearance following parotidectomy for benign disease at high-volume centres.

Parotidectomy carries several well-recognised complications that require preoperative counselling and appropriate management:

• Facial nerve palsy — temporary: The most feared complication. Temporary facial weakness (neuropraxia) from traction, thermal, or ischaemic injury to the nerve occurs in 15–40% of cases after superficial parotidectomy; the vast majority (95%+) recover fully within 6 weeks to 6 months. Higher rates occur after revision surgery, total parotidectomy, and deep lobe removal due to more extensive nerve manipulation.
• Facial nerve palsy — permanent: Permanent paresis from inadvertent nerve division or devascularisation occurs in below 1–2% of cases for benign disease at high-volume centres, rising to 5–10% in re-operative and malignant cases where nerve preservation is more challenging. In radical parotidectomy, nerve sacrifice is deliberate; facial reanimation surgery (cable graft, cross-facial nerve graft, hypoglossal-facial anastomosis, gracilis free flap for dynamic reanimation) is planned preoperatively.
• Frey's syndrome (auriculotemporal syndrome — gustatory sweating): The most common long-term complication, affecting 30–60% of patients after parotidectomy. Caused by aberrant reinnervation of skin sweat glands by secretomotor parasympathetic nerve fibres from the auriculotemporal nerve (which normally innervate the parotid gland) — patients experience facial flushing and sweating in response to eating. Mild cases require no treatment. Botulinum toxin-A (BTX-A) intradermal injection into the affected preauricular skin area is the treatment of choice, providing 6–18 months of relief per treatment cycle, with high patient satisfaction rates (above 90%). Repeat injection is required when symptoms return. Preventive techniques at primary surgery (sternomastoid or superficial musculoaponeurotic system — SMAS — flap interposition between skin and parotid bed) may reduce Frey's syndrome incidence.
• Great auricular nerve anaesthesia: The great auricular nerve (C2/C3) provides sensory innervation to the lower earlobe, parotid region, and angle of the jaw, and crosses the surgical field. Sacrifice of this nerve — unavoidable in some cases — causes permanent numbness of the lower earlobe. Many patients adapt without functional impairment, though some find this distressing.
• Salivary fistula and sialocele: Persistent salivary leakage through the wound (fistula) or subcutaneous salivary collection (sialocele) occurs in 2–5% of cases. Management: pressure dressings, anticholinergic drugs (hyoscine patches to reduce salivary flow), and botulinum toxin injection into residual parotid tissue. Most resolve spontaneously within 4–8 weeks.
• Haematoma: Wound haematoma occurs in 1–3% of cases, typically in the first 12–24 hours post-operatively. Expanding haematoma compressing the airway requires immediate return to theatre.

Structured post-operative follow-up monitors wound healing, facial nerve recovery, tumour surveillance, and late complications:

• Immediate post-operative management (days 0–3): Patients undergoing superficial parotidectomy for benign disease are typically discharged on day 1–2. Wound drains are removed when output is below 30 mL over 8 hours (usually at 24–48 hours). The wound is reviewed at 7–10 days for suture removal. Facial nerve function is documented systematically using the House-Brackmann grading scale at discharge and all follow-up visits.
• First outpatient review (2–4 weeks): Histopathology confirms tumour type, margin status, and any unexpected malignant features. For confirmed benign disease with clear margins, routine surveillance imaging is not required. For unexpected malignant histology, urgent MDT review is convened for re-staging and treatment planning.
• Facial nerve rehabilitation: Patients with postoperative facial weakness (neuropraxia) are referred to a specialist physiotherapist for facial neuromuscular retraining — exercises to prevent synkinesis (involuntary co-movement of facial muscles during recovery) and maximise recovery quality. Eye care is critical in patients with orbicularis oculi weakness — lubricating drops, moisture-chamber spectacles, and nocturnal taping of the eyelid prevent corneal exposure keratopathy and ulceration.
• Malignant parotid tumours — surveillance: Following treatment for malignant parotid tumours, structured surveillance is essential. CAMS/BSOMS and British Head and Neck Cancer Society (BAHNO) guidelines recommend clinical review and MRI neck every 3–6 months for the first 2 years, then 6–12 monthly for years 3–5. Chest CT annually screens for pulmonary metastases (mucoepidermoid carcinoma and adenoid cystic carcinoma have high lung metastasis risk).
• Management of Frey's syndrome: Patients are counselled pre-operatively about Frey's syndrome risk. If symptoms develop (typically 6–18 months post-operatively), minor starch-iodine (Minor's test) can confirm the diagnosis. BTX-A (botulinum toxin-A) injection into the preauricular skin area at doses of 50–100 units provides relief for 9–18 months; repeat injection is well-tolerated and effective long-term.
• Pleomorphic adenoma — long-term surveillance: Formal long-term surveillance imaging is not standard for completely excised pleomorphic adenoma after superficial parotidectomy. However, patients should be instructed to self-report any new preauricular swelling immediately, as even delayed recurrences (10–20 years) may occur. New swelling in the parotid bed after previous excision requires urgent MRI and repeat FNAC.

Parotidectomy costs vary with the extent of surgery, intraoperative monitoring equipment, hospitalisation duration, and whether adjuvant therapy is required:

• Preoperative investigation costs: Parotid ultrasound with FNAC in India costs INR 2,000–6,000 (USD 24–72). MRI parotid with gadolinium costs INR 6,000–18,000 (USD 72–216) in India; USD 1,000–3,000 in the USA. CT neck for malignant staging adds INR 3,000–10,000 (USD 36–120) in India.
• Superficial parotidectomy for benign disease: At private tertiary head and neck surgery centres in India, superficial parotidectomy costs INR 1,00,000–3,00,000 (USD 1,200–3,600) including anaesthesia, histopathology, intraoperative nerve monitoring, and 2–3 nights hospitalisation. In the UK (private), GBP 4,000–8,000 (approximately USD 5,100–10,200). In the USA, USD 12,000–30,000 including all facility and professional fees.
• Total parotidectomy: More extensive procedure costing INR 2,00,000–5,00,000 (USD 2,400–6,000) in India. In the USA, USD 20,000–45,000. Longer operative time and theatre costs account for the higher fee compared to superficial parotidectomy.
• Radical parotidectomy for malignancy with neck dissection: The most complex procedure; in India at specialist oncology centres, costs INR 3,50,000–8,00,000 (USD 4,200–9,600). In the USA, radical parotidectomy with neck dissection and immediate facial nerve reconstruction costs USD 40,000–80,000. Adjuvant radiotherapy (30–33 fractions) adds USD 20,000–50,000 in the USA; INR 3,00,000–8,00,000 in India at private cancer centres (considerably less at government centres or with insurance).
• Intraoperative facial nerve monitoring: Adds USD 300–800 to surgical costs in the USA; INR 5,000–20,000 in India. A critical patient safety investment that reduces permanent palsy risk.
• Botulinum toxin-A for Frey's syndrome: BTX-A injections for Frey's syndrome cost USD 300–700 per treatment session in the USA; INR 5,000–20,000 in India, depending on dosage and centre. Treatment is required every 9–18 months. Some insurers cover BTX-A for Frey's syndrome if appropriately coded.
• Facial reanimation surgery: For patients requiring facial nerve reconstruction after radical parotidectomy, nerve grafting and dynamic reanimation procedures (gracilis free flap, hypoglossal-facial anastomosis) add USD 25,000–60,000 in the USA; INR 3,00,000–10,00,000 in India at specialist plastic and reconstructive surgery centres.

In selected clinical scenarios, non-surgical or less extensive surgical alternatives may be appropriate for parotid pathology:

• Active surveillance for small Warthin's tumour: In elderly or frail patients with a small, asymptomatic, FNAC-confirmed Warthin's tumour and no concerning radiological features, active surveillance with 6–12 monthly parotid ultrasound is a valid management option. Warthin's tumour has virtually zero malignant potential and may remain stable for years. Surveillance avoids surgical risk in patients who may not tolerate general anaesthesia.
• Observation for small benign parotid masses in high-risk surgical patients: Superficial parotidectomy is the standard of care for pleomorphic adenoma, but for elderly patients with multiple comorbidities and small, stable, FNAC-confirmed pleomorphic adenomas, a shared decision-making discussion about the risks and benefits of surgery versus watchful waiting with serial MRI is appropriate, acknowledging the 5–10% malignant transformation risk.
• Sialendoscopy for parotid duct calculi and benign strictures: Minimally invasive endoscopic visualisation and treatment of the parotid duct system can retrieve calculi, dilate strictures, and manage obstructive sialadenitis without parotidectomy in many patients. Success rates for accessible parotid stones with sialendoscopy range from 60–80%, with parotidectomy reserved for endoscopy failures or very large intraparenchymal stones.
• Fine needle aspiration cytology alone for cysts: Simple parotid cysts confirmed on both ultrasound and FNAC as benign (including first branchial cleft cysts in selected cases) may be aspirated as a diagnostic and therapeutic manoeuvre, with surveillance ultrasound thereafter, though recurrence is common and surgery is usually required for symptomatic or enlarging cysts.
• Radiotherapy alone for unresectable malignancy: For patients with locally advanced, unresectable malignant parotid tumours who are medically unfit for surgery, definitive intensity-modulated radiotherapy (IMRT) with or without concurrent chemotherapy offers locoregional control, though cure rates are inferior to combined surgery plus radiotherapy. Palliative radiotherapy is used for metastatic or recurrent disease.
• Enucleation — a cautioned alternative: Simple enucleation (shelling out) of a pleomorphic adenoma without a cuff of parotid tissue was historically practised but is now explicitly not recommended by CAMS/BSOMS and other authoritative guidelines due to the 20–45% local recurrence rate from incomplete pseudocapsule and satellite nodule removal. Recurrent pleomorphic adenoma is multinodular, disseminated, and extremely difficult to manage without facial nerve sacrifice.